Propranolol
Propranolol is a beta-blocker. The US label read, for propranolol hydrochloride tablets (taken by mouth), lists several heart and vessel uses, of which this page records four: hypertension; decreasing angina frequency and increasing exercise tolerance in patients with angina pectoris; controlling the ventricular rate in atrial fibrillation with a rapid ventricular response; and reducing cardiovascular mortality in stable patients who have survived the acute phase of a myocardial infarction. The label also lists another heart use and uses outside the heart, which this page does not record.
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 8787; UNII F8A3652H1V. The label names the substance as propranolol hydrochloride, so UNII F8A3652H1V is the UNII of the hydrochloride salt and is a broad match. MeSH descriptor D011433 is Propranolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Amneal Pharmaceuticals NY LLC label for propranolol hydrochloride tablets, applications ANDA071972 and ANDA071976, effective 2026-06-10 in openFDA. The tablet label of a generic sponsor was read because it is a plain immediate-release tablet label; the Inderal LA, InnoPran XL and Hemangeol labels (other products of the same substance) were not read. This page records label indications and the class only: no trial result and no dose is given. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded.
Trials at a glance
The figures count the 1 registry trial in this atlas that names this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 1
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | All statuses |
|---|---|---|
| Phase 2/3 | 1 | 1 |
| All phases | 1 | 1 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
F8A3652H1V
Claims and evidence
Context People for whom the US label of propranolol hydrochloride tablets lists one of the four heart or vessel indications recorded here: hypertension, angina pectoris, atrial fibrillation with a rapid ventricular response, survivors of the acute phase of myocardial infarction
- Recipient
- Recipient not specified
- Population
- Patients described in the heart and vessel passages of the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 4 inclusion criteria; exclusion criteria not stated
- Included
- Patients with hypertension
- Patients with angina pectoris
- Patients with atrial fibrillation and a rapid ventricular response
- Clinically stable patients who have survived the acute phase of myocardial infarction
- Excluded
- None stated
The US label of Propranolol hydrochloride tablets, in the Amneal Pharmaceuticals NY LLC version dated 2026-06-10 in openFDA, lists the medicine for the management of hypertension; to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response; and to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of myocardial infarction.
Applies to Recipient not specified People for whom the US label of propranolol hydrochloride tablets lists one of the four heart or vessel indications recorded here: hypertension, angina pectoris, atrial fibrillation with a rapid ventricular response, survivors of the acute phase of myocardial infarction
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-06-10
- Source state
- Current
- Version fingerprint
58aa79ab4fa6d5f88acbbfcb992c5236ebf3aee11476e255e1eefae3929e0d7d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260610.
- Retrieved
- Source effective date
- 2026-06-10
- Source state
- Current
- Version fingerprint
58aa79ab4fa6d5f88acbbfcb992c5236ebf3aee11476e255e1eefae3929e0d7d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
HEMANGEOL
No label from the application holder was found in the openFDA label dataset for application NDA205410. This page does not show another labeler's label in its place.
INDERAL
No label from the application holder was found in the openFDA label dataset for application NDA016418. This page does not show another labeler's label in its place.
INDERAL
No label from the application holder was found in the openFDA label dataset for application NDA019536. This page does not show another labeler's label in its place.
INDERAL LA
No label from the application holder was found in the openFDA label dataset for application NDA018553. This page does not show another labeler's label in its place.
INDERIDE LA 80/50
No label from the application holder was found in the openFDA label dataset for application NDA019059. This page does not show another labeler's label in its place.
INDERIDE-40/25
No label from the application holder was found in the openFDA label dataset for application NDA018031. This page does not show another labeler's label in its place.
INNOPRAN XL
No label from the application holder was found in the openFDA label dataset for application NDA021438. This page does not show another labeler's label in its place.
PROPRANOLOL HYDROCHLORIDE
No label from the application holder was found in the openFDA label dataset for application NDA016419. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA016418 - Approval
NDA016419 - Supplemental approval
NDA016418 - Approval
NDA018031 - Supplemental approval
NDA016418 - Approval
NDA018553 - Supplemental approval
NDA016418 - Supplemental approval
NDA018553 - Approval
NDA019059 - Supplemental approval
NDA018553 - Supplemental approval
NDA016418 - Supplemental approval
NDA016418 - Supplemental approval
NDA016418 - Approval
NDA019536 - Supplemental approval
NDA018553 - Supplemental approval
NDA018031 - Approval
NDA021438 - Approval
NDA205410
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists management of hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of propranolol hydrochloride tablets lists one of the four heart or vessel indications recorded here: hypertension, angina pectoris, atrial fibrillation with a rapid ventricular response, survivors of the acute phase of myocardial infarction
The US label of Propranolol hydrochloride tablets, in the Amneal Pharmaceuticals NY LLC version dated 2026-06-10 in openFDA, lists the medicine for the management of hypertension; to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response; and to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists control of ventricular rate in atrial fibrillation with a rapid ventricular response as an indication: Atrial fibrillation (AF)
Applies to Recipient not specified People for whom the US label of propranolol hydrochloride tablets lists one of the four heart or vessel indications recorded here: hypertension, angina pectoris, atrial fibrillation with a rapid ventricular response, survivors of the acute phase of myocardial infarction
The US label of Propranolol hydrochloride tablets, in the Amneal Pharmaceuticals NY LLC version dated 2026-06-10 in openFDA, lists the medicine for the management of hypertension; to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response; and to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reducing cardiovascular mortality after the acute phase of myocardial infarction as an indication: Heart attack (myocardial infarction)
Applies to Recipient not specified People for whom the US label of propranolol hydrochloride tablets lists one of the four heart or vessel indications recorded here: hypertension, angina pectoris, atrial fibrillation with a rapid ventricular response, survivors of the acute phase of myocardial infarction
The US label of Propranolol hydrochloride tablets, in the Amneal Pharmaceuticals NY LLC version dated 2026-06-10 in openFDA, lists the medicine for the management of hypertension; to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response; and to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 8
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 6 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record. FDA lists it under 2 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 3 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 1
Record details
- Record id
cardio:propranolol- Content hash
977dc904e56a1c9095fd9e83a708cab1f569c8640f4f6d61167bc7bec2eb9d15